{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:07:29Z","timestamp":1761692849560,"version":"build-2065373602"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00108-025-02002-3","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:42:40Z","timestamp":1760100160000},"page":"1154-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201eIch kann nicht schlafen!\u201c\u00a0\u2013 Insomnie als h\u00e4ufigste nichtk\u00f6rperliche Schlafst\u00f6rung","\u201cI can\u02bct sleep!\u201d: insomnia as the most common non-organic sleep disorder"],"prefix":"10.1007","volume":"66","author":[{"given":"Ingo","family":"Fietze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2002_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11818-024-00460-9","author":"A Heidbreder","year":"2024","unstructured":"Heidbreder\u00a0A, Kunz\u00a0D, Young\u00a0P, Benes\u00a0H, Chalet\u00a0FX, Vaillant\u00a0C, Kaskel\u00a0P, Fietze\u00a0I, Sch\u00f6bel\u00a0C (2024) Insomnie in Deutschland \u2013 massive Unterversorgung?: Ergebnisse einer prospektiv geplanten Subgruppenanalyse der National Health and Wellness Survey (NHWS). Somnologie. https:\/\/doi.org\/10.1007\/s11818-024-00460-9","journal-title":"Somnologie"},{"key":"2002_CR2","unstructured":"S3-Leitlinie Insomnie bei Erwachsenen (Version 2.0 AWMF-Registernummer: 063-003)"},{"issue":"4","key":"2002_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1378\/chest.14-1617","volume":"147","author":"JC Levenson","year":"2015","unstructured":"Levenson\u00a0JC, Kay\u00a0DB, Buysse\u00a0DJ (2015) The pathophysiology of insomnia. Chest 147(4):1179\u20131192","journal-title":"Chest"},{"issue":"9","key":"2002_CR4","doi-asserted-by":"publisher","first-page":"zsab095","DOI":"10.1093\/sleep\/zsab095","volume":"44","author":"JG Ellis","year":"2021","unstructured":"Ellis\u00a0JG, Perlis\u00a0ML, Espie\u00a0CA, Grandner\u00a0MA, Bastien\u00a0CH, Barclay\u00a0NL, Altena\u00a0E, Gardani\u00a0M (2021) The natural history of insomnia: predisposing, precipitating, coping, and perpetuating factors over the early developmental course of insomnia. Sleep 44(9):zsab95. https:\/\/doi.org\/10.1093\/sleep\/zsab095","journal-title":"Sleep"},{"key":"2002_CR5","unstructured":"American Academy of Sleep Medicine (AASM) Insomnia. https:\/\/aasm.org\/resources\/factsheets\/insomnia.pdf. Zugegriffen: 08.2024"},{"issue":"4","key":"2002_CR6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4103\/2249-4863.201153","volume":"5","author":"S Bhaskar","year":"2016","unstructured":"Bhaskar\u00a0S, Hemavathy\u00a0D, Prasad\u00a0S (2016) Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J\u00a0Family Med Prim Care 5(4):780\u2013784","journal-title":"J Family Med Prim Care"},{"key":"2002_CR7","unstructured":"Bocksch\u00a0R (2023) 43% der Deutschen haben Schlafprobleme. https:\/\/de.statista.com\/infografik\/29586\/befragte-die-unter-schlafstoerungen-leiden\/"},{"key":"2002_CR8","unstructured":"Hafner\u00a0M, Romanelli\u00a0RJ, Yerushalmi\u00a0E, Troxel\u00a0WM (2023) Die gesellschaftlichen und wirtschaftlichen Belastungen durch Schlaflosigkeit bei Erwachsenen \u2013 Eine internationale Studie. RAND Europe. https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/research_reports\/RRA2100\/RRA2166-1\/RAND_RRA2166-4.summary-German.pdf"},{"key":"2002_CR9","doi-asserted-by":"crossref","unstructured":"Spiegelhalder K et\u00a0al (2025) Leitlinie \u201eInsomnie bei Erwachsenen\u201c \u2013 Update 2025. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/063-003 (AWMF-Registernummer 063-003)","DOI":"10.1007\/s11818-025-00530-6"},{"key":"2002_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/15402002.2025.2539961","author":"M Carpi","year":"2025","unstructured":"Carpi\u00a0M, Marques\u00a0DR, Liguori\u00a0C (2025) Deriving subtypes from the insomnia severity index: a\u00a0latent class analysis and comparison of features. Behav Sleep Med. https:\/\/doi.org\/10.1080\/15402002.2025.2539961","journal-title":"Behav Sleep Med"},{"issue":"2","key":"2002_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5664\/jcsm.8988","volume":"17","author":"JD Edinger","year":"2021","unstructured":"Edinger\u00a0JD, Arnedt\u00a0JT, Bertisch\u00a0SM, Carney\u00a0CE, Harrington\u00a0JJ, Lichstein\u00a0KL, Sateia\u00a0MJ, Troxel\u00a0WM, Zhou\u00a0ES, Kazmi\u00a0U, Heald\u00a0JL, Martin\u00a0JL (2021) Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J\u00a0Clin Sleep Med 17(2):263\u2013298","journal-title":"J Clin Sleep Med"},{"issue":"19","key":"2002_CR12","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.2009.682","volume":"301","author":"CM Morin","year":"2009","unstructured":"Morin\u00a0CM, Valli\u00e8res\u00a0A, Guay\u00a0B, Ivers\u00a0H, Savard\u00a0J, M\u00e9rette\u00a0C, Bastien\u00a0C, Baillargeon\u00a0L (2009) Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a\u00a0randomized controlled trial. JAMA 301(19):2005\u20132015","journal-title":"JAMA"},{"issue":"2","key":"2002_CR13","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia\u00a0MJ, Buysse\u00a0DJ, Krystal\u00a0AD, Neubauer\u00a0DN, Heald\u00a0JL (2017) Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline. J\u00a0Clin Sleep Med 13(2):307\u2013349","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"2002_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.sleep.2005.06.004","volume":"6","author":"T Roth","year":"2005","unstructured":"Roth\u00a0T, Walsh\u00a0JK, Krystal\u00a0A, Wessel\u00a0T, Roehrs\u00a0TA (2005) An evaluation of the efficacy and safety of eszopiclone over 12\u00a0months in patients with chronic primary insomnia. Sleep Med 6(6):487\u2013495. https:\/\/doi.org\/10.1016\/j.sleep.2005.06.004","journal-title":"Sleep Med"},{"issue":"2","key":"2002_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot\u00a0E, Mayleben\u00a0D, Fietze\u00a0I, Leger\u00a0D, Zammit\u00a0G, Bassetti\u00a0CLA, Pain\u00a0S, Kinter\u00a0DS, Roth\u00a0T (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trials. Lancet Neurol 21(2):125\u2013139","journal-title":"Lancet Neurol"},{"issue":"6","key":"2002_CR16","doi-asserted-by":"publisher","first-page":"zsaa275","DOI":"10.1093\/sleep\/zsaa275","volume":"44","author":"ML Boof","year":"2021","unstructured":"Boof\u00a0ML, Dingemanse\u00a0J, Lederer\u00a0K, Fietze\u00a0I, Ufer\u00a0M (2021) Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep 44(6):zsaa275. https:\/\/doi.org\/10.1093\/sleep\/zsaa275","journal-title":"Sleep"},{"issue":"4","key":"2002_CR17","doi-asserted-by":"publisher","first-page":"e13248","DOI":"10.1111\/jsr.13248","volume":"30","author":"ML Boof","year":"2021","unstructured":"Boof\u00a0ML, Dingemanse\u00a0J, Brunke\u00a0M, Esselmann\u00a0A, Heymer\u00a0P, Kestermann\u00a0O, Lederer\u00a0K, Fietze\u00a0I, Ufer\u00a0M (2021) Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J\u00a0Sleep Res 30(4):e13248. https:\/\/doi.org\/10.1111\/jsr.13248","journal-title":"J Sleep Res"},{"key":"2002_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/JMDH.S337053","volume":"15","author":"BD Saputra","year":"2022","unstructured":"Saputra\u00a0BD, Levita\u00a0J, Mustarichie\u00a0R (2022) Efficacy, safety, and drug-drug interactions for insomnia therapy in COVID-19\u00a0patients. J\u00a0Multidiscip Healthc 15:137\u2013152","journal-title":"J Multidiscip Healthc"},{"issue":"5","key":"2002_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/archpsyc.65.5.551","volume":"65","author":"M Pollack","year":"2008","unstructured":"Pollack\u00a0M, Kinrys\u00a0G, Krystal\u00a0A, McCall\u00a0WV, Roth\u00a0T, Schaefer\u00a0K, Rubens\u00a0R, Roach\u00a0J, Huang\u00a0H, Krishnan\u00a0R (2008) Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 65(5):551\u2013562","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"2002_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.biopsych.2006.01.016","volume":"59","author":"M Fava","year":"2006","unstructured":"Fava\u00a0M, McCall\u00a0WV, Krystal\u00a0A, Wessel\u00a0T, Rubens\u00a0R, Caron\u00a0J, Amato\u00a0D, Roth\u00a0T (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59(11):1052\u20131060","journal-title":"Biol Psychiatry"},{"key":"2002_CR21","doi-asserted-by":"publisher","unstructured":"Ragsdale\u00a0SM, Radovich\u00a0JM, Coiduras\u00a0II, McCall\u00a0WV, Grant\u00a0SC, Lee\u00a0C, Wilber\u00a0A (2025) Dual orexin receptor antagonists as promising therapeutics for Alzheimer\u2019s disease. NPJ Biol Timing Sleep 2(1):11. https:\/\/doi.org\/10.1038\/s44323-025-00025-5","DOI":"10.1038\/s44323-025-00025-5"},{"issue":"1","key":"2002_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5664\/jcsm.11334","volume":"21","author":"J Boer","year":"2025","unstructured":"Boer\u00a0J, Toncar\u00a0T, Stange\u00a0A, Rosenblum\u00a0L, Fietze\u00a0I (2025) Effect of graduated drug therapy for moderate-to-severe chronic insomnia on the severity of disease: an observational study in Germany. J\u00a0Clin Sleep Med 21(1):33\u201345","journal-title":"J Clin Sleep Med"},{"key":"2002_CR23","first-page":"50","volume":"17","author":"I D\u00e4nschel","year":"2024","unstructured":"D\u00e4nschel\u00a0I, Fietze\u00a0I (2024) Chronische Schlafst\u00f6rungen: Ein Therapievorschlag. Hausarzt 17:50\u201354","journal-title":"Hausarzt"},{"key":"2002_CR24","unstructured":"Weltgesundheitsorganisation (WHO) (2021) Internationale Klassifikation der Krankheiten, Elfte Revision (ICD-11). https:\/\/icd.who.int\/browse11"},{"key":"2002_CR25","volume-title":"The international classification of sleep disorders (ICSD-3)","year":"2014","unstructured":"American Academy of Sleep Medicine (Hrsg) (2014) The international classification of sleep disorders (ICSD-3), 3.\u00a0Aufl.","edition":"3"},{"key":"2002_CR26","first-page":"863","volume":"120","author":"W Freund","year":"2023","unstructured":"Freund\u00a0W, Weber\u00a0F (2023) Funktion des Schlafs und Behandlung der prim\u00e4ren Insomnie. The function of sleep and the treatment of primary insomnia. Dtsch \u00c4rztebl Int 120:863\u2013870","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"3","key":"2002_CR27","first-page":"177","volume":"13","author":"I Fietze","year":"2018","unstructured":"Fietze\u00a0I (2018) \u00c4rztl Psychother 13(3):177\u2013181","journal-title":"\u00c4rztl Psychother"},{"issue":"1","key":"2002_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ana.26641","volume":"94","author":"BP Lucey","year":"2023","unstructured":"Lucey\u00a0BP, Liu\u00a0H, Toedebusch\u00a0CD, Freund\u00a0D, Redrick\u00a0T, Chahin\u00a0SL, Mawuenyega\u00a0KG, Bollinger\u00a0JG, Ovod\u00a0V, Barth\u00e9lemy\u00a0NR, Bateman\u00a0RJ (2023) Suvorexant acutely decreases tau phosphorylation and abeta in the human CNS. Ann Neurol 94(1):27\u201340","journal-title":"Ann Neurol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02002-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02002-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T19:37:16Z","timestamp":1761680236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02002-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02002-3","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"17 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0Fietze gibt an, Berater f\u00fcr Idorsia, Lilly, Takeda zu sein und Vortr\u00e4ge f\u00fcr Berlin-Chemie, Hennig, Idorsia, Lilly zu halten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}